AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19681255 — intervention group
Group type: COMPARATOR
Intervention: Placebo brush-applied gel without peroxide
Number of subjects: 72
Study 15186865 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day teaching program for diabetic patients
Number of subjects: 319
Study 15186865 — intervention group
Group type: COMPARATOR
Intervention: Control group of 241 insulin-treated patients
Number of subjects: 319
Study 11769568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 48
Study 11769568 — intervention group
Group type: COMPARATOR
Intervention: Sham-smoking
Number of subjects: 48
Study 11769568 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers' group
Number of subjects: 48
Study 9744782 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation for stress urinary incontinence
Number of subjects: 10
Study 9744782 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation for urge urinary incontinence
Number of subjects: 10
Study 8046692 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 financial incentive
Number of subjects: 517
Study 8046692 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 financial incentive
Number of subjects: 517
Study 8046692 — intervention group
Group type: COMPARATOR
Intervention: Early responders
Number of subjects: 517
Study 8046692 — intervention group
Group type: COMPARATOR
Intervention: Late responders
Number of subjects: 517
Study 2494686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate therapy
Number of subjects: 122
Study 2494686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 30921183 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 111
Study 30921183 — intervention group
Group type: COMPARATOR
Intervention: Standard uncoated balloon
Number of subjects: 111
Study 28422526 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG)
Number of subjects: 59
Study 28422526 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group (CG)
Number of subjects: 59
Study 26308684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil
Number of subjects: 500
Study 26308684 — intervention group
Group type: COMPARATOR
Intervention: Ambrisentan monotherapy (10 mg)
Number of subjects: 500
Study 26308684 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil monotherapy (40 mg)
Number of subjects: 500
Study 26308684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 500
Study 23038021 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered black tea solids containing 429 mg of polyphenols
Number of subjects: 111
Study 23038021 — intervention group
Group type: COMPARATOR
Intervention: Control product matched in flavour and caffeine content but containing no tea solids
Number of subjects: 111
Study 22045080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adenosine (24 mg)
Number of subjects: 20
Study 22045080 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adenosine (36 mg)
Number of subjects: 20
Study 22045080 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (both doses)
Number of subjects: 20
Study 19961025 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified CPAP
Number of subjects: 125
Study 19961025 — intervention group
Group type: COMPARATOR
Intervention: Dry CPAP
Number of subjects: 125
Study 19961025 — intervention group
Group type: COMPARATOR
Intervention: CPAP with fluticasone
Number of subjects: 125
Study 19961025 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (dry, fluticasone, humidifier)
Number of subjects: 125
Study 16982235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 1424
Study 16982235 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 1424
Study 15569335 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (2 g/day)
Number of subjects: 45
Study 15569335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10767752 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred consulting style
Number of subjects: 161
Study 10767752 — intervention group
Group type: COMPARATOR
Intervention: Doctor-centred consulting style
Number of subjects: 161
Study 10767752 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching a poor prognosis video
Number of subjects: 161
Study 10767752 — intervention group
Group type: EXPERIMENTAL
Intervention: Being employed in a professional occupation
Number of subjects: 161
Study 9306037 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of oral glucose
Number of subjects: 46
Study 9306037 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of intravenous glucagon
Number of subjects: 46
Study 9306037 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment for 10-14 days in 15 poorly controlled NIDDM patients
Number of subjects: 46
Study 9306037 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 46
Study 8371179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral appliances (IA)
Number of subjects: 110
Study 8371179 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback and stress management (BF/SM)
Number of subjects: 110
Study 8371179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IA and BF/SM
Number of subjects: 110
Study 8371179 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 110
Study 3723621 — intervention group
Group type: EXPERIMENTAL
Intervention: Antishock trousers inflated to 50 mm Hg
Number of subjects: 8
Study 3723621 — intervention group
Group type: EXPERIMENTAL
Intervention: Antishock trousers inflated to 100 mm Hg
Number of subjects: 8
Study 29189045 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 80
Study 29189045 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 80
Study 27671178 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional methacrylate based composite using incremental technique (Group A, n=40)
Number of subjects: 120
Study 27671178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stress methacrylate resin based composite SDR using single step technique (Group B, n=40)
Number of subjects: 120
Study 24719474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5HVR48.EnvA.01 vaccine (10^9 to 10^11 viral particles)
Number of subjects: 48
Study 24719474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22699098 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Speed Treadmill Training Exercise Program (SSTTEP)
Number of subjects: 26
Study 22699098 — intervention group
Group type: COMPARATOR
Intervention: Strengthening exercise program
Number of subjects: 26
Study 20207324 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention group
Number of subjects: 56
Study 20207324 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest group
Number of subjects: 56
Study 18754438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.00 mg/kg (0.15%-0.20%)
Number of subjects: 200
Study 18754438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.25 mg/kg (0.20%-0.25%)
Number of subjects: 200
Study 18754438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.50 mg/kg (0.30%-0.35%)
Number of subjects: 200
Study 18754438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2.00 mg/kg (0.30%-0.35%)
Number of subjects: 200
Study 16483488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus vinorelbine (NL group)
Number of subjects: 102
Study 16483488 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus vinorelbine (NP group)
Number of subjects: 102
Study 12592683 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treated group (CWT + DSQ)
Number of subjects: 64
Study 12592683 — intervention group
Group type: COMPARATOR
Intervention: Conventional western therapy (CWT)
Number of subjects: 64
Study 10379638 — intervention group
Group type: COMPARATOR
Intervention: Clozapine 12.5 mg alone
Number of subjects: 12
Study 10379638 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 12.5 mg with erythromycin 1500 mg
Number of subjects: 12
Study 9295496 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified element diet (dextrin as glycogen) via nasal feeding tube
Number of subjects: 20
Study 9295496 — intervention group
Group type: COMPARATOR
Intervention: Common nutritional support method
Number of subjects: 20
Study 1870835 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxium (calcium dobesilate) 500 mg, 3 capsules daily for 6 months
Number of subjects: 79
Study 1870835 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 capsules daily for 6 months
Number of subjects: 79
Study 7038483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin
Number of subjects: 25
Study 7038483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31269891 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized palmitoylethanolamide 600 mg/die
Number of subjects: 0
Study 31269891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28334632 — intervention group
Group type: EXPERIMENTAL
Intervention: Average sleep duration at 4th grade
Number of subjects: 0
Study 28334632 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control at 5th grade
Number of subjects: 0
Study 28334632 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend bed-time delay at 4th grade
Number of subjects: 0
Study 28334632 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend wake-time delay at 4th grade
Number of subjects: 0
Study 28334632 — intervention group
Group type: EXPERIMENTAL
Intervention: Reductions in nightly sleep
Number of subjects: 0
Study 25827448 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia arjuna (500 mg twice a day)
Number of subjects: 116
Study 25827448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 23063141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 7.5mg
Number of subjects: 259
Study 23063141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5mg
Number of subjects: 259
Study 23063141 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker therapy (continued without modification)
Number of subjects: 259
Study 21564523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin (300 mg b.i.d.)
Number of subjects: 125
Study 21564523 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (control)
Number of subjects: 125
Study 18356022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard splints
Number of subjects: 45
Study 18356022 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft splints
Number of subjects: 45
Study 18356022 — intervention group
Group type: COMPARATOR
Intervention: No splint (Control)
Number of subjects: 45
Study 16849748 — intervention group
Group type: COMPARATOR
Intervention: rIFL (reduced-dose bolus fluorouracil plus leucovorin and irinotecan)
Number of subjects: 305
Study 16849748 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (infused fluorouracil plus leucovorin and oxaliplatin)
Number of subjects: 305
Study 16849748 — intervention group
Group type: COMPARATOR
Intervention: rIFL
Number of subjects: 305
Study 16849748 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 305
Study 16849748 — intervention group
Group type: COMPARATOR
Intervention: rIFL and FOLFOX4
Number of subjects: 305
Study 12170038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 60
Study 12170038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 60
Study 12170038 — intervention group
Group type: COMPARATOR
Intervention: Rescue dextropropoxyphene tablets
Number of subjects: 60
Study 12170038 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 60
Study 12170038 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic toxicity or catheter infection
Number of subjects: 60
Study 10446825 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha (1.25, 12.5, 125, or 250 pg/mL for 20 mins)
Number of subjects: 0
Study 10446825 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1beta (6.25, 12.5, 50, or 200 pg/mL for 20 mins)
Number of subjects: 0
Study 10446825 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha (1.25 pg/mL) plus IL-1beta (6.25 pg/mL)
Number of subjects: 0
Study 10446825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramidase inhibitor N-oleoyl ethanolamine (1 microM) or NO synthase inhibitor N(G)-monomethyl-L-arginine (10 microM)
Number of subjects: 0
Study 7597397 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured expander prostheses
Number of subjects: 20
Study 7597397 — intervention group
Group type: COMPARATOR
Intervention: Smooth expander prostheses
Number of subjects: 20
Study 2085967 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380A (ParaGard)
Number of subjects: 0
Study 2085967 — intervention group
Group type: COMPARATOR
Intervention: Comparative devices (Lippes Loop D, TCu 200, TCu 220, Multiload Cu 250)
Number of subjects: 0
Study 313765 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (n = 120) received a bolus of hypertonic glucose, insulin, and potassium in the pump perfusate before aortic cross‐clamping.
Number of subjects: 391
Study 313765 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (n = 114) had the aortic root continuously infused with glucose, insulin, and potassium solution at 4 degrees C during aortic cross‐clamping.
Number of subjects: 391
Study 313765 — intervention group
Group type: COMPARATOR
Intervention: Control Group 1 (n = 157) received no additional glucose, insulin, and potassium solutions.
Number of subjects: 391
Study 7045433 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 64
Study 7045433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31237191 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg CBD
Number of subjects: 34
Study 31237191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29386049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of autologous bone marrow mononuclear cells and standard neurorehabilitation
Number of subjects: 58
Study 29386049 — intervention group
Group type: COMPARATOR
Intervention: Standard neurorehabilitation
Number of subjects: 58
Study 26809243 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-gallate (EGCG) supplementation for 48 weeks
Number of subjects: 86
Study 26809243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 24574125 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (0.25 mg)
Number of subjects: 40
Study 24574125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22356215 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) orally disintegrating tablets (ODT) and CR capsules (50 mg)
Number of subjects: 0
Study 22356215 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) syrup (reference)
Number of subjects: 0
Study 21044101 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 supplement (TheraTears Nutrition®)
Number of subjects: 61
Study 21044101 — intervention group
Group type: COMPARATOR
Intervention: Wheat germ oil
Number of subjects: 61
Study 17568957 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored text messages delivered via handheld computers
Number of subjects: 40
Study 17568957 — intervention group
Group type: COMPARATOR
Intervention: Control group using handheld computers for daily surveys
Number of subjects: 40
Study 15930540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose shock wave therapy without anesthetic
Number of subjects: 114
Study 15930540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 15930540 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover patients receiving active treatment after placebo
Number of subjects: 114
Study 15930540 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activity scores and overall impression of disease state
Number of subjects: 114
Study 11845223 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg/day for 6 days)
Number of subjects: 8
Study 10417465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen insufflation at a constant flow of 21.min‐1
Number of subjects: 60
Study 10417465 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Ophthalmic drape A
Number of subjects: 60
Study 10417465 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Ophthalmic drape B
Number of subjects: 60
Study 10417465 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Ophthalmic drape C
Number of subjects: 60
Study 7573241 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic excision
Number of subjects: 40
Study 7573241 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study 2205624 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined estrogen/progestogen therapy (2 mg estradiol + 1 mg norethisterone acetate + 500 mg calcium daily)
Number of subjects: 40
Study 2205624 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 500 mg calcium daily
Number of subjects: 40
Study 6992626 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral terbutaline
Number of subjects: 8
Study 6992626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6992626 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline t.i.d. for a week
Number of subjects: 8
Study 31231863 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 1748
Study 31231863 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1748
Study 27137171 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-Can (FC)
Number of subjects: 34
Study 27137171 — intervention group
Group type: EXPERIMENTAL
Intervention: Empty-Can (EC)
Number of subjects: 34
Study 27137171 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Horizontal Abduction (PHA)
Number of subjects: 34
Study 28194194 — intervention group
Group type: EXPERIMENTAL
Intervention: Islam-based religious program (8 sessions)
Number of subjects: 52
Study 24386900 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly, physiotherapist-led exercise classes
Number of subjects: 1000
Study 24386900 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for care home staff
Number of subjects: 1000
Study 24386900 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups
Number of subjects: 1000
Study 21593280 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole once daily for 7 days
Number of subjects: 27
Study 19942720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular electrical stimulation at latent MTrPs
Number of subjects: 13
Study 19942720 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation of tibial nerve
Number of subjects: 13
Study 17457161 — intervention group
Group type: EXPERIMENTAL
Intervention: Binding pancreaticojejunostomy
Number of subjects: 217
Study 17457161 — intervention group
Group type: COMPARATOR
Intervention: Conventional pancreaticojejunostomy
Number of subjects: 217
Study 14744832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 0
Study 12067876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 33
Study 12067876 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure
Number of subjects: 33
Study 9797593 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training and conventional medical treatment (BFT)
Number of subjects: 29
Study 9797593 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment alone (Control)
Number of subjects: 29
Study 9346036 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week water safety and swimming lessons
Number of subjects: 109
Study 9346036 — intervention group
Group type: COMPARATOR
Intervention: 8 week water safety and swimming lessons
Number of subjects: 109
Study 2694330 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine treatment for 4 weeks
Number of subjects: 128
Study 2694330 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study 848514 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-categories transfer condition
Number of subjects: 72
Study 848514 — intervention group
Group type: EXPERIMENTAL
Intervention: New-categories group
Number of subjects: 72
Study 848514 — intervention group
Group type: COMPARATOR
Intervention: Random and blocked format lists
Number of subjects: 72
Study 31968301 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-treatment frequency of use
Number of subjects: 0
Study 31968301 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-treatment abstinence
Number of subjects: 0
Study 31968301 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of days of use
Number of subjects: 0
Study 30575054 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (Group A)
Number of subjects: 450
Study 30575054 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) antibiotic for 1 day (Group B)
Number of subjects: 450
Study 30575054 — intervention group
Group type: COMPARATOR
Intervention: 1 day IV plus 7 days oral antibiotic (Group C)
Number of subjects: 450
Study 28421639 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol (50 mg twice a day)
Number of subjects: 84
Study 28421639 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study 26537207 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary sentinel lymph node (SSLN) tracing technique with Methylthioninium chloride injection in group A (138 patients)
Number of subjects: 247
Study 26537207 — intervention group
Group type: COMPARATOR
Intervention: Standard D2 radical gastrectomy in group B (109 patients)
Number of subjects: 247
Study 23789213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dingqi analgesic patch
Number of subjects: 40
Study 23789213 — intervention group
Group type: COMPARATOR
Intervention: Sham patch (Control)
Number of subjects: 40